Humoral and cellular immune response to Sars-CoV-2 wild-type and variants of concern following 3-dose vaccination in a large cohort of adults with cancer: The SerOzNET study.
Eva Segelov(University of Bern), Elizabeth Ahern(Monash Health), Katie E. Lineburg(QIMR Berghofer Medical Research Institute), Sudha Rao(QIMR Berghofer Medical Research Institute), Vi Luong(Monash Health), Stuart Turville(UNSW Sydney), Veronica Aedo Lopez(Monash Health), Hesham Abdulla(Suez Canal University), Robert McCuaig(University of Canberra), C. Raina MacIntyre(UNSW Sydney), Luxi Lal(Monash Health), Stephen Opat(Monash Health), Amy Body(Monash Health), Zin Naing(New South Wales Department of Health), Corey Smith(QIMR Berghofer Medical Research Institute)
Cited by 0
Related Papers
Estimates of global seasonal influenza-associated respiratory mortality: a modelling study
|The Lancet|2017|3.1k
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
|Blood|2019|369
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
|Cancer Discovery|2019|272
Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients.
|Journal of Clinical Pathology|1984|261